Filana Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Filana Therapeutics Inc.
- Former names
- Cassava Sciences Inc Pain Therapeutics Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Austin
- Headquarters state / province
- Texas
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- FLNA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001069530
- EIN
- 91-1911336
Board of directors
-
Claude Nicaise · DirectorSince 2023
-
Dawn Carter Bir · DirectorSince 2025
-
Donnell Michael J. O. · DirectorSince 2023
-
Nadav Friedmann · Director · Chief Medical OfficerSince 2023
-
Patrick J. Md Scannon Ph.D. · DirectorSince 2023
-
Pierre Gravier · DirectorSince 2023
-
Remi Barbier · Director · President & CEOSince 2023
-
Richard Barry · Director · President & CEOSince 2023
-
Robert Eugene Anderson Jr. · DirectorSince 2023
-
Robert Z. Gussin · DirectorSince 2023
-
Sanford Robertson · DirectorSince 2023
Chief executives
Richard Barry
· President & CEO
Dates unknown
Remi Barbier
· President and CEO
Dates unknown
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
85.0%
-
85.7%
-
87.1%
Board connections
4 of this board's directors also sit on 5 other boards.
- via Claude Nicaise and Richard Barry
- via Claude Nicaise
- via Claude Nicaise
- via Dawn Carter Bir
- via Sanford Robertson
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $680,689
- 4 purchases by 3 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 24, 2025 | Robert Eugene Anderson Jr. Director | Open-market purchase | +8,600 | $2.90 | $24,940 |
| Nov 20, 2025 | Richard Barry Director, Officer (President & CEO) | Open-market purchase | +150,000 | $2.76 | $414,000 |
| Nov 19, 2025 | Richard Barry Director, Officer (President & CEO) | Open-market purchase | +73,385 | $2.75 | $201,809 |
| Sep 30, 2025 | Cook Robert Christopher Officer (Chief Operating & Legal Office) | Open-market purchase | +13,725 | $2.91 | $39,940 |
| Sep 22, 2025 | Richard Barry Director, Officer (President & CEO) | Open-market purchase | +7,172 | $2.28 | $16,352 |
| Sep 19, 2025 | Richard Barry Director, Officer (President & CEO) | Open-market purchase | +400 | $2.25 | $900 |
| Sep 19, 2025 | Richard Barry Director, Officer (President & CEO) | Open-market purchase | +46,908 | $2.29 | $107,419 |
| Sep 18, 2025 | Richard Barry Director, Officer (President & CEO) | Open-market purchase | +5,400 | $2.13 | $11,502 |
| Sep 18, 2025 | Richard Barry Director, Officer (President & CEO) | Open-market purchase | +185,233 | $2.24 | $414,922 |
| Nov 29, 2024 | Kupiec James William Officer (Chief Medical Officer) | Open-market sale | −4,000 | $3.87 | $15,480 |
| Nov 29, 2024 | Schoen Eric Officer (Chief Financial Officer) | Option exercise | +50,000 | $1.18 | $59,000 |
| Nov 29, 2024 | Schoen Eric Officer (Chief Financial Officer) | Open-market sale | −2,000 | $3.82 | $7,640 |
| Nov 29, 2024 | Schoen Eric Officer (Chief Financial Officer) | Open-market sale | −59,800 | $3.86 | $230,828 |
| May 16, 2024 | Sanford Robertson Director | Gift | −5,000 | — | — |
| May 16, 2024 | Sanford Robertson Director | Gift | +5,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.